HRT and the risk of deep vein thrombosis

Dispensed prescription medications and short-term risk of pulmonary embolism in Norway and Sweden

Scandinavian electronic health-care registers provide a unique setting to investigate potential unidentified side effects of drugs. We analysed the association between prescription drugs dispensed in Norway and Sweden and the short-term risk of developing pulmonary embolism. A total of 12,104 pulmonary embolism cases were identified from patient- and cause-of-death registries in Norway (2004-2014) and 36,088 in Sweden (2005-2014). A case-crossover design was used to compare individual drugs dispensed 1-30 days before the date of pulmonary embolism diagnosis with dispensation in a 61-90 day time-window, while controlling for the receipt of other drugs. A BOLASSO approach was used to select drugs that were associated with short-term risk of pulmonary embolism. Thirty-eight drugs were associated with pulmonary embolism in the combined analysis of the Norwegian and Swedish data. Drugs associated with increased risk of pulmonary embolism included certain proton-pump inhibitors, antibiotics, antithrombotics, vasodilators, furosemide, anti-varicose medications, corticosteroids, immunostimulants (pegfilgrastim), opioids, analgesics, anxiolytics, antidepressants, antiprotozoals, and drugs for cough and colds. Mineral supplements, hydrochlorothiazide and potassium-sparing agents, beta-blockers, angiotensin 2 receptor blockers, statins, and methotrexate were associated with lower risk. Most associations persisted, and several additional drugs were associated, with pulmonary embolism when using a longer time window of 90 days instead of 30 days. These results provide exploratory, pharmacopeia-wide evidence of medications that may increase or decrease the risk of pulmonary embolism. Some of these findings were expected based on the drugs' indications, while others are novel and require further study as potentially modifiable precipitants of pulmonary embolism.

Post menopausal hormones and measures of subclinical atherosclerosis: the multi-ethnic study of atherosclerosis

OBJECTIVE

To evaluate whether post menopausal hormones are associated with atherosclerosis.

METHODS

We studied the relation of hormone use to coronary calcification and carotid intima-media thickness in a cross-sectional sample of 3245 post menopausal women, of whom 1620 had used hormones for various periods. Adjusted associations with three measures of hormone use (ever use, duration, and type of hormone) were estimated by multivariable regression.

RESULTS

The prevalence of coronary calcification was only 4 percentage points lower in women who had ever used hormones than in women who had not (40% versus 44%), and was not monotonically related to longer use: <2 years: 38%; 2-6 years: 36%; 6-13 years: 41%; >13 years: 48%. Similarly, duration of hormone use did not show a monotonic dose-response relation with the calcium score. Mean differences in carotid intima-media thickness according to categories of years of hormone use and type of hormone ranged from -0.10 mm to +0.08 mm, with no consistent patterns. Most adjusted associations were weak and sometimes contrary to our expectation.

CONCLUSIONS

We did not find meaningful associations between hormone use and subclinical atherosclerosis-neither to support benefit or harm, nor to support the prevailing theory of "healthy user" bias (namely, inverse associations due to residual confounding).

Pulmonary embolism and cardiac enzymes

BACKGROUND

Pulmonary embolism (PE) is often associated with chest pain, electrocardiographic changes, and right ventricular (RV) dysfunction on echocardiogram. There have been reports of elevated troponin levels with PE. RV dysfunction and elevated troponin levels have prognostic implications in acute PE. The purpose of this retrospective analysis was to determine whether PE was associated with elevated cardiac enzymes and whether there was any difference among patients who presented with or without chest pain.

METHODS

Records of 93 consecutive patients with high-probability ventilation/perfusion lung scan results for PE were analyzed for the presence or absence of chest pain on presentation, abnormalities in cardiac enzymes, and evidence of RV dysfunction on echocardiogram.

RESULTS

A total of 56 of 93 patients had cardiac enzymes evaluated; 24 of these 56 patients had chest pains, and 32 did not. Only 1 patient of the 56 had abnormal cardiac enzymes. This patient had a known history of coronary artery disease (CAD) and had experienced an acute anterior myocardial infarction. Echocardiograms were performed in 36 of 93 patients. Evidence of RV dysfunction on echocardiograms was found in 22 of these patients. No significant relationship was found between RV dysfunction and chest pains (P > .10).

CONCLUSION

We found no significant relationship between high-probability ventilation/perfusion scan results and abnormalities in cardiac enzymes irrespective of the presence or absence of chest pain. Patients with a history of CAD or RV dysfunction did not have a higher incidence of chest pain when compared with those with no known history of CAD or RV dysfunction.

Effect of a fish-oil concentrate on serum lipids in postmenopausal women receiving and not receiving hormone replacement therapy in a placebo-controlled, double-blind trial

BACKGROUND

n-3 Fatty acid supplementation lowered serum triacylglycerol concentrations in studies in which most of the subjects were male. The effects of n-3 fatty acid supplementation in postmenopausal women receiving and not receiving hormone replacement therapy (HRT) have received little attention.

OBJECTIVE

We sought to determine the effects of a fish-oil-derived n-3 fatty acid concentrate on serum lipid and lipoprotein risk factors for cardiovascular disease in postmenopausal women receiving and not receiving HRT, with an emphasis on serum triacylglycerol concentrations and the ratio of triacylglycerol to HDL cholesterol.

DESIGN

Postmenopausal women (n = 36) were grouped according to exogenous hormone use and were randomly allocated to receive 8 capsules/d of either placebo oil (control) or n-3 fatty acid-enriched oil (supplement). The supplement provided 2.4 g eicosapentaenoic acid (EPA) plus 1.6 g docosahexaenoic acid (DHA) daily. Serum lipids and the fatty acid composition of serum phospholipids were determined on days 0 and 28.

RESULTS

Supplementation with n-3 fatty acids was associated with 26% lower serum triacylglycerol concentrations (P < 0.0001), a 28% lower overall ratio of serum triacylglycerol to HDL cholesterol (P < 0.01), and markedly greater EPA and DHA concentrations in serum phospholipids (P < 0.05).

CONCLUSIONS

These results show that supplementation with a fish-oil-derived concentrate can favorably influence selected cardiovascular disease risk factors, particularly by achieving marked reductions in serum triacylglycerol concentrations and triacylglycerol:HDL cholesterol in postmenopausal women receiving and not receiving HRT. This approach could potentially reduce the risk of coronary heart disease by 27% in postmenopausal women.

Postmenopausal hormone therapy into the 21st century

At the time of the menopause, a review of the major health issues can be especially rewarding. Besides the general issues of good health, particular attention is now being focused on prevention of cardiovascular disease and osteoporosis because of the potentially beneficial effects of postmenopausal hormone therapy. Hormone therapy should be offered to most women as they consider their paths for successful aging. However, as for any pharmacological intervention, the benefits of treatment must outweigh the risk. The available data would appear to indicate that, for most women, this is in fact the case with current research into future hormonal therapies aimed at further improving the benefit:risk ratio.